OsteoCure Therapeutics, Inc

What it does

"OsteoCure Therapeutics, Inc. is a groundbreaking lifetech and medtech company focused on revolutionizing bone health through their innovative adenosine platform. By developing two lead programs, OCTA1 and OCTA2, OsteoCure offers localized therapies for fracture and fusion repair, as well as systemic treatments for osteoporosis. Their adenosine platform, utilizing a naturally occurring molecule, delivers tailored solutions for acute injury repair and chronic bone loss, outperforming current standards. With a strong foundation in Duke University research and validation through preclinical studies, OsteoCure is positioned to make a significant impact in orthopedic repair and osteoporosis treatment markets. Led by a team of experts, including co-founders Hunter Newman, PhD, and Shyni Varghese, PhD, OsteoCure is poised for early clinical advancements and strategic partnerships in the industry."